Who
Ulf Wiinberg
Director
Company insider
Files Form 4 as: Director, MiNK Therapeutics; Director, Agenus; Sr. VP&Pres. Wyeth Pharm EMEA, Wyeth.
In numbers
- Trades disclosed
- 113
- Buys
- 4
- Sells
- 3
- Bought
- $235K
- Sold
- $9.0M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 8 May 2002
- Last trade
- 1 Sep 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 2 Sep 2026 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $14K1,279 at $10.95 | filing |
| 1 Sep 2026filed 2 Sep 2026 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $14K1,279 at $10.95 | filing |
| 1 Jun 2026filed 2 Jun 2026 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $14K1,131 at $12.38 | filing |
| 1 Jun 2026filed 2 Jun 2026 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $14K1,131 at $12.38 | filing |
| 2 Mar 2026filed 2 Jun 2026 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $14K1,285 at $10.90 | filing |
| 2 Mar 2026filed 2 Jun 2026 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $14K1,285 at $10.90 | filing |
| 2 Jan 2026filed 6 Jan 2026 | INKT MiNK Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,395 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | INKT MiNK Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,395 at $0.00 | filing |
| 1 Dec 2025filed 3 Dec 2025 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $14K1,263 at $11.09 | filing |
| 9 Sep 2025filed 11 Sep 2025 | INKT MiNK Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,225 at $0.00 | filing |
| 2 Sep 2025filed 3 Sep 2025 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $14K1,011 at $13.86 | filing |
| 2 Jun 2025filed 4 Jun 2025 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $14K1,953 at $7.17 | filing |
| 3 Mar 2025filed 5 Mar 2025 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $14K1,593 at $8.79 | filing |
| 1 Dec 2024filed 3 Dec 2024 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $15K20,476 at $0.73 | filing |
| 1 Oct 2024filed 3 Oct 2024 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,423.48 | filing |
| 3 Sep 2024filed 5 Sep 2024 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $15K18,295 at $0.82 | filing |
| 1 Jul 2024filed 1 Jul 2024 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,121.12 | filing |
| 3 Jun 2024filed 5 Jun 2024 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $15K15,077 at $0.99 | filing |
| 1 Apr 2024filed 1 Apr 2024 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,635.46 | filing |
| 1 Mar 2024filed 5 Mar 2024 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $15K15,790 at $0.95 | filing |
News
ImageneBio (NASDAQ:IMA) versus Agenus (NASDAQ:AGEN) Financial SurveyAGEN · dailypolitical.com · 11 Oct 2026Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal CancerAGEN · elliotlakestandard.ca · 8 Oct 2026
0 headlines in the last 90 days name Ulf Wiinberg; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.